Hans Holger Fischer

3.1k total citations
6 papers, 101 citations indexed

About

Hans Holger Fischer is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Hans Holger Fischer has authored 6 papers receiving a total of 101 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Cancer Research and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Hans Holger Fischer's work include Breast Cancer Treatment Studies (5 papers), Cancer Treatment and Pharmacology (5 papers) and HER2/EGFR in Cancer Research (3 papers). Hans Holger Fischer is often cited by papers focused on Breast Cancer Treatment Studies (5 papers), Cancer Treatment and Pharmacology (5 papers) and HER2/EGFR in Cancer Research (3 papers). Hans Holger Fischer collaborates with scholars based in Germany, Taiwan and France. Hans Holger Fischer's co-authors include K. M. Schrott, A. Altendorf-Hofmann, Jürgen Dunst, Rolf Sauer, Nadia Harbeck, Oleg Gluz, Ulrike Nitz, W. Kühn, Christine zu Eulenburg and Katja Krauss and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Hans Holger Fischer

6 papers receiving 101 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hans Holger Fischer Germany	5	63	48	30	26	20	6	101
Charlotte S. Voskuilen Netherlands	10	149 2.4×	54 1.1×	12 0.4×	60 2.3×	25 1.3×	16	184
P. Céliz Spain	3	87 1.4×	41 0.9×	21 0.7×	15 0.6×	33 1.6×	7	126
Ariel Ann Nelson United States	6	50 0.8×	65 1.4×	8 0.3×	7 0.3×	21 1.1×	28	111
Amanda Nizam United States	7	58 0.9×	48 1.0×	6 0.2×	6 0.2×	30 1.5×	32	93
Bijun Lian China	6	31 0.5×	27 0.6×	31 1.0×	7 0.3×	72 3.6×	17	103
Yuanyuan Bao China	5	55 0.9×	83 1.7×	6 0.2×	7 0.3×	32 1.6×	14	125
Zaid Viney United Kingdom	4	84 1.3×	26 0.5×	4 0.1×	31 1.2×	88 4.4×	5	156
Alberto Gil-Jimenez Netherlands	5	74 1.2×	48 1.0×	4 0.1×	7 0.3×	16 0.8×	6	107
Bajorin Df United States	5	47 0.7×	19 0.4×	8 0.3×	4 0.2×	12 0.6×	6	73
Philip J.S. Charlesworth United Kingdom	4	22 0.3×	18 0.4×	39 1.3×	4 0.2×	40 2.0×	7	102

Countries citing papers authored by Hans Holger Fischer

Since Specialization

Citations

This map shows the geographic impact of Hans Holger Fischer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans Holger Fischer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans Holger Fischer more than expected).

Fields of papers citing papers by Hans Holger Fischer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans Holger Fischer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans Holger Fischer. The network helps show where Hans Holger Fischer may publish in the future.

Co-authorship network of co-authors of Hans Holger Fischer

This figure shows the co-authorship network connecting the top 25 collaborators of Hans Holger Fischer. A scholar is included among the top collaborators of Hans Holger Fischer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans Holger Fischer. Hans Holger Fischer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

Harbeck, Nadia, Oleg Gluz, Matthias Christgen, et al.. (2021). De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results.. Journal of Clinical Oncology. 39(15_suppl). 503–503. 11 indexed citations

Schneeweiß, Andreas, Sibylle Loibl, Eleftherios P. Mamounas, et al.. (2019). Patient-reported outcomes (PROs) from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.. Journal of Clinical Oncology. 37(15_suppl). 513–513. 4 indexed citations

Nitz, Ulrike, Oleg Gluz, Matthias Christgen, et al.. (2016). Final analysis of WSG-ADAPT HER2+/HR- trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant dual blockade with trastuzumab + pertuzumab ± weekly paclitaxel in HER2+/HR- early breast cancer (EBC).. Journal of Clinical Oncology. 34(15_suppl). 518–518. 8 indexed citations

Nitz, Ulrike, Jens Huober, B. Lisboa, et al.. (2009). Superiority of sequential docetaxel over standard FE100C in patients with intermediate risk breast cancer: survival results of the randomized intergroup phase III trial EC-Doc.. Cancer Research. 69(2_Supplement). 78–78. 8 indexed citations

Huober, Jens, B. Lisboa, Nadia Harbeck, et al.. (2008). Interim results of Intergroup EC-Doc Trial: A randomized multicenter phase III trial comparing adjuvant CEF/CMF to EC- docetaxel in patients with 1–3 positive lymph nodes. Journal of Clinical Oncology. 26(15_suppl). 515–515. 3 indexed citations

Sauer, Rolf, et al.. (1990). Radiotherapy with and without cisplatin in bladder cancer. International Journal of Radiation Oncology*Biology*Physics. 19(3). 687–691. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact